Phio Pharmaceuticals Corp. — Director's Dealing 2026

Feb 6, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Phio Pharmaceuticals Corp. (PHIO)
CIK: 0001533040
Period of Report: 2026-02-05

Reporting Person: Lockshin Curtis (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-02-05	Common Stock, $.0001 par value	A	16600	—	Acquired	35155	Direct

Footnotes

F1: Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant.

F2: Includes shares of common stock underlying unvested restricted stock units.

F3: The number of reported securities has been adjusted to reflect prior reverse stock splits.